#USA #Florida #Actimab-A #Actinium Pharmaceuticals #Iomab-ACT

Actinium Pharmaceuticals Highlights Milestones at Mar-a-Lago

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has recently held a significant business update at the prestigious Trump Mar-a-Lago Club in Florida. This event showcased the company’s advancements in targeted radiotherapies, particularly focusing on its clinical programs—Actimab-A and Iomab-ACT—both of which are designed to tackle critical healthcare challenges in oncology.

During the presentation, Sandesh Seth, the chairman and CEO of Actinium, expressed pride in the company’s recent achievements. He articulated the enthusiasm surrounding their clinical programs, which are anticipated to yield substantial milestones in 2025. This optimism comes from a robust pipeline aimed at addressing unmet medical needs across various cancer treatments.Essentially, the company is focusing on opportunities within three major multi-billion-dollar markets: myeloid malignancies, solid tumors, and cell and gene therapy conditioning.

Revitalized Clinical Programs

Actinium's revitalized clinical programs are expected to make significant progress in the coming months. Some highlights of their strategy include:

1. Actimab-A: A mutation-agnostic treatment for myeloid malignancies like acute myeloid leukemia (AML). This product is poised to enter a Phase 2/3 trial in combination with chemotherapy, aiming to generate initial clinical data within specific trial collaborations.

2. Solid Tumor Indications: Actimab-A is also being explored as a pan-solid tumor therapy. Combining it with PD-1 inhibitors like KEYTRUDA and OPDIVO aims to deplete myeloid-derived suppressor cells, and initial clinical proof of concept studies are planned for head and neck cancers.

3. Iomab-ACT: This is being developed as a universal conditioning agent to enhance patient access to innovative cell and gene therapies. The company is set to present initial clinical data from an ongoing commercial CAR-T trial.

Expanding Manufacturing Capabilities

As part of its growth strategy, Actinium is also investing significantly into its research, development, and manufacturing infrastructure. The company is excited about the upcoming construction of a new manufacturing facility anticipated to begin next quarter. This facility aims to leverage proprietary cyclotron manufacturing technology essential for producing Actinium-225, a radioisotope key to their therapies.

Furthermore, Actinium currently holds 230 patents, with a focus on augmenting preclinical programs targeting solid tumors. This innovative approach underscores the company’s commitment to developing therapies that could meaningfully improve patient outcomes across diverse cancer types.

Looking Ahead

Mr. Seth highlighted the multifaceted opportunities ahead as the company gears up for clinical successes. With a strategically robust balance sheet, Actinium is positioned well into mid-2027, allowing the team to focus on executing its plans and creating value. The ambitious roadmap involves substantial clinical development efforts aimed at establishing Actimab-A and Iomab-ACT as major players in their respective markets.

In conclusion, Actinium Pharmaceuticals is at the forefront of revolutionary treatments in oncology. The Mar-a-Lago presentation shed light on its exciting future and the potential impacts these therapies could have on patient care and cancer treatment efficacy. Stay tuned as more developments unfold from this innovative biotechnology company.